Birmingham Capital Management Co. Inc. AL Makes New $2.71 Million Investment in Pfizer Inc. $PFE

Birmingham Capital Management Co. Inc. AL acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, Holdings Channel.com reports. The fund acquired 112,751 shares of the biopharmaceutical company’s stock, valued at approximately $2,715,000. Pfizer accounts for 1.0% of Birmingham Capital Management Co. Inc. AL’s holdings, making the stock its 29th largest holding.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Bluefin Capital Management LLC acquired a new stake in Pfizer during the 2nd quarter valued at $459,000. Magnolia Capital Advisors LLC lifted its holdings in Pfizer by 4.5% in the 2nd quarter. Magnolia Capital Advisors LLC now owns 16,265 shares of the biopharmaceutical company’s stock worth $392,000 after buying an additional 705 shares in the last quarter. Port Capital LLC boosted its position in Pfizer by 6.6% in the 2nd quarter. Port Capital LLC now owns 9,442 shares of the biopharmaceutical company’s stock valued at $227,000 after buying an additional 583 shares during the last quarter. Freestone Grove Partners LP grew its stake in shares of Pfizer by 314.8% during the second quarter. Freestone Grove Partners LP now owns 335,530 shares of the biopharmaceutical company’s stock valued at $8,080,000 after acquiring an additional 254,644 shares in the last quarter. Finally, Gallagher Fiduciary Advisors LLC increased its position in shares of Pfizer by 4.3% during the second quarter. Gallagher Fiduciary Advisors LLC now owns 30,148 shares of the biopharmaceutical company’s stock worth $726,000 after acquiring an additional 1,235 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PFE has been the topic of several recent analyst reports. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. Weiss Ratings lowered Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 17th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a report on Tuesday, June 9th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. Finally, BMO Capital Markets decreased their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.28.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer has started a European Medicines Agency review for its Lyme disease vaccine. The review is an important regulatory step that could expand Pfizer’s longer-term vaccine portfolio, although it does not guarantee approval or near-term revenue. Pfizer Starts EMA Review For Its Lyme Disease Vaccine
• Positive Sentiment: Recent comparisons with Bristol Myers Squibb suggest Pfizer’s valuation, diversification and oncology portfolio may offer an attractive risk-reward profile. This supports the view that the stock could benefit if new medicines successfully offset declining legacy-product sales. PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
• Positive Sentiment: Analysts are focused on Pfizer’s post-second-quarter pipeline and whether upcoming medicines can reset the company’s growth trajectory. The opportunity is meaningful because Pfizer recently exceeded quarterly earnings and revenue expectations, but execution remains key. How Is Pfizer Shaping Its S&P 500 Pipeline After Q2?
• Neutral Sentiment: Pfizer’s dividend remains appealing to income-oriented investors, but comparisons with Abbott Laboratories emphasize that Pfizer offers more turnaround potential while Abbott has a steadier dividend-growth record and broader diversification. Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
• Neutral Sentiment: Brokerages collectively rate Pfizer “Hold,” indicating that analysts see potential value but lack a strong consensus catalyst for a decisive re-rating. Pfizer Receives Consensus Recommendation of Hold
• Negative Sentiment: Investor caution persists over Pfizer’s need to restore growth before major patent expirations arrive. Articles discussing new medicines frame the pipeline as necessary to counterbalance expected pressure on established products, limiting enthusiasm until launches and approvals produce measurable results. Can New Medicines Reset the Growth Story?

Pfizer Stock Performance

Shares of PFE stock opened at $28.33 on Thursday. The stock has a market capitalization of $161.47 billion, a price-to-earnings ratio of 37.28 and a beta of 0.34. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75. The company’s 50-day simple moving average is $25.44 and its 200-day simple moving average is $26.29. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the company earned $0.78 earnings per share. Pfizer’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is 226.32%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.